Loading company…
Jerusalem company founded in 2016 developing TPC1022, an oral immunomodulatory compound for autoimmune diseases.
Founded in 2016 and based in Jerusalem, Israel, TPCera develops TPC1022, an oral immunomodulatory compound. It is intended for autoimmune diseases by shifting the immune system's inflammatory state into an anti-inflammatory one.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in